RVNC — Revance Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual cashflow statement for Revance Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-159	-282	-281	-356	-324
Depreciation
Deferred Taxes
Non-Cash Items	16.1	56.1	44.7	128	140
Unusual Items
Other Non-Cash Items
Changes in Working Capital	34.3	40	-4.77	0.665	-43.9
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	-106	-179	-222	-194	-217
Capital Expenditures	-3.24	-4.22	-10.4	-3.21	-6.89
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-14.4	16.3	-19.3	-136	117
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-17.6	12.1	-29.7	-139	110
Financing Cash Flow Items	-2.12	-37.7	-8.53	-8.19	-9.06
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	222	331	29.9	332	137
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	97.9	165	-221	-0.652	29.7